Search

Your search keyword '"Smit, E F"' showing total 425 results
Start Over Author "Smit, E F"
425 results on '"Smit, E F"'

1. Tumoren van de long, mediastinum en pleura

Author

Schramel, F. M. N. H., Kastelijn, E. A., Aerts, J. G. J. V., Hofman, F. N., Seldenrijk, C. A., Senan, S., Smit, E. F., Spoelstra, F. O. B., Herder, G. J. M., Kummer, J. A., van Krieken, J.H.J.M., editor, Beets-Tan, R.G.H., editor, Gelderblom, A.J., editor, Olofsen, M.J.J., editor, and Rutten, H.J.T., editor

Published
2020
Full Text
View/download PDF

2. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Author

van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., Nederlof, P. M., van Herpen, C. M. L., de Groot, D. J. A., Devriese, L. A., Hoeben, A., de Jonge, M. J. A., Chalabi, M., Smit, E. F., de Langen, A. J., Mehra, N., Labots, M., Kapiteijn, E., Sleijfer, S., Cuppen, E., Verheul, H. M. W., Gelderblom, H., and Voest, E. E.

Published
2019
Full Text
View/download PDF

3. Tumoren van de long, mediastinum en pleura

Author

Schramel, F. M. N. H., Aerts, J. G. J. V., Herder, G. J. M., Hofman, F. N., Kummer, J. A., Seldenrijk, C. A., Senan, S., Smit, E. F., Spoelstra, F. O. B., van de Velde, C.J.H., editor, van der Graaf, W.T.A., editor, van Krieken, J.H.J.M., editor, and Marijnen, C.A.M., editor

Published
2017
Full Text
View/download PDF

5. One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

Author

van der Veldt, A A M, Oosting, S F, Fehrmann, R S N, GeurtsvanKessel, C H, van Binnendijk, R S, Dingemans, A-M C, Smit, E F, Hiltermann, T J N, Hartog, G den, Jalving, M, Westphal, T T, Bhattacharya, A, de Wilt, F, Ernst, S M, Boerma, A, van Zijl, L, Rimmelzwaan, G F, Kvistborg, P, van Els, C A C M, Rots, N Y, van Baarle, D, Haanen, J B A G, de Vries, E G E, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Translational Immunology Groningen (TRIGR), Targeted Gynaecologic Oncology (TARGON), Medical Oncology, Radiology & Nuclear Medicine, Virology, and Pulmonary Medicine

Subjects
Cancer Research, Oncology, SDG 3 - Good Health and Well-being
Published
2023

7. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Author

Niemeijer, A. N., Leung, D., Huisman, M. C., Bahce, I., Hoekstra, O. S., van Dongen, G. A. M. S., Boellaard, R., Du, S., Hayes, W., Smith, R., Windhorst, A. D., Hendrikse, N. H., Poot, A., Vugts, D. J., Thunnissen, E., Morin, P., Lipovsek, D., Donnelly, D. J., Bonacorsi, S. J., Velasquez, L. M., de Gruijl, T. D., Smit, E. F., and de Langen, A. J.

Published
2018
Full Text
View/download PDF

8. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

Author

Powell, C. A., Modi, S., Iwata, H., Takahashi, S., Smit, E. F., Siena, S., Chang, D. Y., Macpherson, E., Qin, A., Singh, J., Taitt, C., Shire, N., Camidge, D. Ross, and CCA - Cancer Treatment and quality of life

Subjects
interstitial lung disease, Cancer Research, Immunoconjugates, adverse event, pneumonitis, Pneumonia, Trastuzumab, trastuzumab deruxtecan, Oncology, HER2, Humans, Camptothecin, Lung Diseases, Interstitial, Aged, Retrospective Studies
Abstract

Introduction: This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd) monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in patients treated with T-DXd. Methods: Patients who received T-DXd across nine studies were included. Investigator-assessed ILD/pneumonitis events were retrospectively reviewed by an independent adjudication committee; events adjudicated as drug-related ILD/pneumonitis are summarized. Results: The analysis included 1150 patients (breast cancer, 44.3%; gastric cancer, 25.6%; lung cancer, 17.7%; colorectal cancer, 9.3%; other cancer, 3.0%). Median treatment duration was 5.8 (range, 0.7-56.3) months, with a median of 4 (range, 1-27) prior lines of therapy. The overall incidence of adjudicated drug-related ILD/pneumonitis was 15.4% (grade 5, 2.2%). Most patients with ILD/pneumonitis experienced low-grade events (grade 1 or 2, 77.4%); 87.0% had their first event within 12 months [median, 5.4 (range, 6.4 mg/kg, oxygen saturation 4 years. Conclusions: In this pooled analysis of heavily treated patients, the incidence of ILD/pneumonitis was 15.4%, with most being low grade and occurring in the first 12 months of treatment. The benefit–risk of T-DXd treatment is positive; however, some patients may be at increased risk of developing ILD/pneumonitis, and further investigation is needed to confirm ILD/pneumonitis risk factors. Close monitoring and proactive management of ILD/pneumonitis are warranted for all.

Published
2022

9. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

Author

Kerr, K M, Dafni, U, Schulze, K, Thunnissen, E, Bubendorf, L, Hager, H, Finn, S, Biernat, W, Vliegen, L, Losa, J H, Marchetti, A, Cheney, R, Warth, A, Speel, E -J, Blackhall, F, Monkhorst, K, Jantus Lewintre, E, Tischler, V, Clark, C, Bertran-Alamillo, J, Meldgaard, P, Gately, K, Wrona, A, Vandenberghe, P, Felip, E, De Luca, G, Savic, S, Muley, T, Smit, E F, Dingemans, A -M C, Priest, L, Baas, P, Camps, C, Weder, W, Polydoropoulou, V, Geiger, T R, Kammler, R, Sumiyoshi, T, Molina, M A, Shames, D S, Stahel, R A, and Peters, S

Published
2018
Full Text
View/download PDF

14. Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors

Author

Oosting, S., Van der Veldt, A. A. M., GeurtsvanKessel, C. H., Fehrmann, R. S. N., Van Binnendijk, R. S., Dingemans, A-M. C., Smit, E. F. F., Hiltermann, T. J. N., Den Hartog, G., Jalving, M., Westphal, T., Battacharya, A., van der Heiden, M., Blank, C. U., Koopmans, M. P., van Els, C. A., Rots, N. Y., van Baarle, D., Haanen, J. B. A. G., de Vries, E. G., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Translational Immunology Groningen (TRIGR), and Targeted Gynaecologic Oncology (TARGON)

Published
2021

17. A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)

Author

Reck, M., Mileham, K., Paz-Ares, L., Surmont, V., Felip, E., Vinolas, N., Bessudo, A., Clump, D., Decoster, L., Estival, A., Sebastian, M., Chen, H., Chisamore, M., Wagner, V. J., Wagner, A., Smit, E. F. F., Clinical sciences, Medical Oncology, and Laboratory of Molecular and Medical Oncology

Abstract

Background: Nivolumab or pembrolizumab is the standard second-line treatment for patients (pts) with advanced NSCLC. Anlotinib is an oral VEGFR, FGFR, PDGFR and c-Kit tyrosine kinase inhibitor. The interaction between tumor immune microenvironment and angiogenesis has been well established.This study was designed to assess the benefit and optimal time of nivolumab or pembrolizumab plus anlotinib in previously treated advanced NSCLC. Methods: This is a prospective observational study. Pts with advanced NSCLC who had previous progression after platinum-based chemotherapy were eligible. For NSCLC with EGFR variations pts who had disease progression with prior EGFR TKI therapies and chemotherapy were also eligible. Nivolumab on day 1 (3 mg/kg) every 2 weeks or pembrolizumab on day 1 (200 mg) every 3 weeks for up to 8 weeks, for pts who have no symptomatic deterioration and can benefit from the treatment, then followed by the former therapy plus anlotinib maintenance until progression or unacceptable toxic effects. Anlotinib was given orally 12mg for 2 weeks of a 21-day cycle (days 1-14). The primary outcome was ORR. The secondary outcomes were DCR, PFS, OS and safety. Results: From Mar-2019 to Apr-2021, a total of 19 pts were enrolled. Most were male (84.2%), adenocarcinoma histology (68.4%) and most were treated as second-line treatment (57.9%). 4 had baseline brain metastases. For 8 weeks’ treatment of nivolumab or pembrolizumab monotherapy, 5 pts achieved PR, 8 pts achieved SD and 6 pts had PD; ORR was 26.3%, DCR was 73.7%. During the anti-PD-1 therapy plus anlotinib, 1 pt achieved CR, 12 pts achieved PR (4 of them were PD during monotherapy), 4 pts achieved SD. ORR was 68.4%, DCR was 89.5%. Median PFS was 13.1 months (95% CI 8.6 to14.9). Grade 3 TRAE occurred in 26% pts. 2 pts with squamous cell carcinoma died due to pulmonary embolism and respiratory tract hemorrhage. The most common TRAE were fatigue, hypothyroidism and rash. Conclusions: Anti-PD-1 therapy plus anlotinib has shown promising anti-tumor efficacy compared to the previous anti-PD-1 monotherapy studies for pts with previously treated advanced NSCLC, and with a tolerable safety profile. We may focus on exploring the optimal time and advantage group of this combination in future studies.

Published
2021

18. A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

Author

Dingemans, A-M. C., Ernst, S., Mellema, W., Burgers, S., Staal-Van den Brekel, J., Hendriks, L. E. L., Hiltermann, T. J. N., Van Walree, N., Maas, K., Youssef-ElSoud, M., Biesma, B., Van Noord, V., Smit, E. F. F., De langen, J. A., and Translational Immunology Groningen (TRIGR)

Published
2021

20. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Author

Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E. F., Syrigos, K., Stahel, R., Felip, E., Peters, S., Stahel, Rolf, Felip, Enriqueta, Peters, Solange, Kerr, Keith, Besse, Benjamin, Vansteenkiste, Johan, Eberhardt, Wilfried, Edelman, Martin, Mok, Tony, OʼByrne, Ken, Novello, Silvia, Bubendorf, Lukas, Marchetti, Antonio, Baas, Paul, Reck, Martin, Syrigos, Konstantinos, Paz-Ares, Luis, Smit, Egbert F., Meldgaard, Peter, Adjei, Alex, Nicolson, Marianne, Crinò, Lucio, Van Schil, Paul, Senan, Suresh, Faivre-Finn, Corinne, Rocco, Gaetano, Veronesi, Giulia, Douillard, Jean-Yves, Lim, Eric, Dooms, Christophe, Weder, Walter, De Ruysscher, Dirk, Le Pechoux, Cecile, De Leyn, Paul, and Westeel, Virginie

Published
2014
Full Text
View/download PDF

24. Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis

Author

Verstegen, N. E., Oosterhuis, J. W. A., Palma, D. A., Rodrigues, G., Lagerwaard, F. J., van der Elst, A., Mollema, R., van Tets, W. F., Warner, A., Joosten, J. J. A., Amir, M. I., Haasbeek, C. J. A., Smit, E. F., Slotman, B. J., and Senan, S.

Published
2013
Full Text
View/download PDF

37. Abstracts of papers and posters Meeting on Pharmaceutical Sciences

Author

Coile, Jr., Russell C., Wiedhaup, K., van Bommel, Ilva, Mol, Miriam, de Vries, Michiel, Massey, E. W., Biller, J., Davis, J. N., Adams, H. P., Marler, J. R., Magnani, H. N., Schotte, A., Janssen, P. F. M., Leysen, J. E., Skrabanja, A. T. P., Flendrig, L., van Iren, F., Schrijnemakers, E. W. M., Reinhoud, P. J., Kijne, J. W., Knevelman, A., de Wit, H. J. C., de Vries, J. D., Bult, A., Beijnen, J. H., van Winden, E. C. A., Talsma, H., Crommelin, D. J. A., Storm, G., Oussoren, C., Zuidema, J., Vingerhoeds, M. H., Smit, R. H. P., Dinther, F. v., Hultermans, T., Beumer, T., Fransz, A. N., Vromans, H., Bloemhof, D. A., van Mansvelt, F. J. W., Brouwers, J. R. B. J., Raemaekers, J., Boskma, R. J., Bloemhof, H., de Graaf, S. S. N., Uges, D. R. A., Kosterink, J. G. W., de Jonge, M. W. A., Smit, E. F., Kengen, R. A. M., de Leij, L., Piers, D. A., Shochat, D., The, T. H., Luurtsema, Gert, Franssen, Eric, Visser, Geb, Jeronimus-Stratingh, Margot, Bruins, Andries, Vaalburg, Wim, Luurtsema, G., Medema, J., Elsinga, P. H., Franssen, E. J. F., Visser, G. M., Vaalburg, W., Jmker, Jan I., Uges, Donald R. A., van der Paauw, Hugo, Maas, Max, de Vos, Henk, Hettelaar, Jenny, Slolk, L. M. L., van den Brand, W., Smit, B. J., Franssen, R. M. E., Vinks, A. A. T. M. M., Touw, D. J., Heijerman, H. G. M., Danhof, M., Bakker, W., Hermans, J., Driessen G. J., Wolters R., Go I. H., Fennis J., Gribnau F. W. J., Heerdink, Eibert R., Leufkens, Hubert G., Bakker, Albert, Heerdink, E. R., Lau, H. S., Bakker, A., Porsius, A. J., Beuning, K. S., Postma-Lim, E., de Boer, A., Nagtegaal, J. E., Stecher, N., Sturkenboom, M. C. J. M., de Jong-van den Berg, L. T. W., Cornel, M. C., Stricker, B. H. Ch., Wesseling, H., van den Bemt, P. M. L. A., Kil, P. J. M., Meyboom, R. H. B., de Koning, G. H. P., Herings, Ron M. C., Stricker, Bruno H. Ch., Leufkens, Hubert G. M., Urquhart, John, de Boer, Anthonius, Sturmans, Ferd, Middeibeek, Alma, Sturkenboom, Miriam C. J. M., de Jong-van den Berg, Lolkje T. W., Lammers, M. W., Hekster, Y. A., Keyser, A., Meinardi, H., Renier, W. O., Van Lier, H., Veehof, L., Stewart, R., Mevboom-de Jong, B., Haaijer-Ruskamp, F. M., Visser, L. E., van der Velden, J., Paes, A. H. P., van Mil, J. W. F., Tromp, Th. F. J., Casparie, M. K., Kuijpers, A., Stuvt, P. M. J., Dijkers, F. W., vd Ree, C. M., Ruben, B. A., Mokkink, H. G. A., Post, D., Gubbels, J. W., Stokx, L. J., Foets, M., Florax, C., van Dijk, A., Peters, E. T. J., van der Werf, G. T., Denig, P., Boerkamp, Ellis J. C., Haaijer-Ruskamp, Flora M., Reuyl, Jan C., Versluis, Albert, van Trigtv, Anke M., de Jong- vd Berg, Lolkie T. W., Willems, Jaap, Kaldeway, Hans, Wieringa, Nicolien, Herxheimer, Andrew, Vos, Rein, Heijman, Jennifer, Rikken, Floor, Omta S. W. F., Bouter L. M., van Engelen J. M. L., Leufkens, H. G. M., Steffens, B., Thijssen, J. J. H., de Boer, D., Tissot van Patot, H. A., Leusink, J. A., de Jongh, B. M., Reuvers, Inge H., van der Galiën, Trea A., Tromp, Dick F. J., Hendrikx, N. E. H. W., van der Werf, G. Th., Vos, R., Swart, J. A. A., Haisma, H. J., Borchert, J. C. H., Versantvoort, M. W., van Steenbergen, M. J., Hennink, W. E., Wolthuis, W. N. E., van Hooff, R. J. M., Wientjes, K. J. C., Schmidt, F. J., Schoonen, A. J. M., Te Wierik, G. H. P., Eissens, A. C., Lerk, C. F., Haas, M., Iwema Bakker, W. I., Reinhoudt, D. N., Mijer, D. K. F., de Zeeuw, D., Proost, J. H., Wierda, J. M. K. H., Meijer, D. K. F., Kuipers, M., Swart, P. J., Hendriks, M. M. W. B., Kamps, J. A. A. M., Struska, B., Thomas, C., Nijenhuis, A. M., Scherphof, G. L., Swaan, Peter W., Stehouwer, Marco C., Blok, Eric J. C., Tukker, Josef J., van Dijk, J., Gorissen, H. R. M., Groot-Padberg, Y. M., Olling M., van Gelderen C. E. M., Salomons P., Barends D. M., Meulenbelt J., Rauws A. G., Craane-van Hinsberg, W. H. M., Verhoef, J. C., Junginger, H., and Boddé, H. E.

Published
1993
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results